Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends

More ups and downs in July with earnings season hitting its peak and trade threats and denials coming in every couple of days led to accelerated buying culminating in around $4,400 in fresh capital deployed.
Earnings season often triggers some remarkable selloffs and rallies but this time I felt it was more extreme. The "highlight" was certainly Facebook's (FB) massive 25% crash on weaker growth outlooks for quarters or years to come. Intel's (INTC) almost 9% nosedive following great results paired with anxiety about further delays in its 10nm chip infrastructure was also something rare. My two favorite dividend stocks, Altria (MO) and AT&T (T) got hammered as well, both reaching fresh 52-week lows and briefly trading as if their terminal decline is on the cards before rebounding afterwards.
And finally, AbbVie (ABBV) got hammered as well after Citron Research (I have no idea why they have any credibility whatsoever) came out with two strong reports (actually it was one but in order to manifest their weird thesis they decided to publish it again...) to short the stock on the all-too-well-known concerns that AbbVie's Humira flagship product will face biosimilar competition rather soon.
I trimmed some holdings like AT&T, Altria and Gilead and invested in other downbeaten names like AbbVie. Meanwhile, after the post-earnings drops I already repurchased those names.
Portfolio Changes | 3 new stocks, 1 sale, 4 trims and 21 repurchases I... Read more